Acumen Pharmaceuticals, Inc. financial data

Symbol
ABOS on Nasdaq
Location
427 Park St., Charlottesville, VA
State of incorporation
Delaware
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2024 - Aug 13, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 2.3K % +8.02%
Debt-to-equity 12.6 % +192%
Return On Equity -24.6 % +2.84%
Return On Assets -21.9 % +10%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 60.1M shares +3.82%
Common Stock, Shares, Outstanding 60.1M shares +46.4%
Entity Public Float 134M USD -0.89%
Common Stock, Value, Issued 6K USD +50%
Weighted Average Number of Shares Outstanding, Basic 60.1M shares +46.4%
Weighted Average Number of Shares Outstanding, Diluted 60.1M shares +46.4%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 56.5M USD +53%
General and Administrative Expense 20.2M USD +31.9%
Operating Income (Loss) -76.7M USD -46.8%
Nonoperating Income (Expense) 11.8M USD +106%
Net Income (Loss) Attributable to Parent -64.9M USD -39.5%
Earnings Per Share, Basic -1.11 USD/shares +2.63%
Earnings Per Share, Diluted -1.11 USD/shares +2.63%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 68M USD
Marketable Securities, Current 193M USD +185%
Other Assets, Current 405K USD +94.7%
Assets, Current 267M USD +78.5%
Property, Plant and Equipment, Net 105K USD -22.8%
Operating Lease, Right-of-Use Asset 325K USD +1021%
Other Assets, Noncurrent 425K USD +104%
Assets 289M USD +62.9%
Accounts Payable, Current 4.21M USD +108%
Employee-related Liabilities, Current 1.84M USD +34.9%
Accrued Liabilities, Current 4M USD +68.7%
Liabilities, Current 15.4M USD +80.1%
Operating Lease, Liability, Noncurrent 219K USD
Liabilities 45M USD +427%
Accumulated Other Comprehensive Income (Loss), Net of Tax -164K USD +74.6%
Retained Earnings (Accumulated Deficit) -258M USD -33.5%
Stockholders' Equity Attributable to Parent 244M USD +44.5%
Liabilities and Equity 289M USD +62.9%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -17.9M USD -75.5%
Net Cash Provided by (Used in) Financing Activities 7.11M USD
Net Cash Provided by (Used in) Investing Activities -9.2M USD +78.1%
Common Stock, Shares Authorized 300M shares 0%
Common Stock, Shares, Issued 60.1M shares +46.4%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 68.2M USD -11.7%
Interest Paid, Excluding Capitalized Interest, Operating Activities 756K USD
Deferred Tax Assets, Valuation Allowance 33.7M USD +52.2%
Deferred Tax Assets, Gross 34.1M USD +54%
Operating Lease, Liability 344K USD +228%
Depreciation 16K USD +14.3%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -64.4M USD -39.4%
Lessee, Operating Lease, Liability, to be Paid 388K USD
Operating Lease, Liability, Current 125K USD +331%
Lessee, Operating Lease, Liability, to be Paid, Year Two 158K USD
Lessee, Operating Lease, Liability, to be Paid, Year One 155K USD
Operating Lease, Weighted Average Discount Rate, Percent 0.1 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 44K USD +1000%
Lessee, Operating Lease, Liability, to be Paid, Year Three 158K USD
Deferred Tax Assets, Operating Loss Carryforwards 16.6M USD +26.1%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 0 USD
Operating Lease, Payments 38K USD -5%
Additional Paid in Capital 502M USD +38.4%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 437K USD +1357%
Share-based Payment Arrangement, Expense 8.19M USD +76.5%
Interest Expense 1M USD
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%